Semaxanib

CAS No. 194413-58-6

Semaxanib ( SU5416 )

Catalog No. M13045 CAS No. 194413-58-6

Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 37 In Stock
10MG 30 In Stock
25MG 48 In Stock
50MG 71 In Stock
100MG 111 In Stock
200MG 174 In Stock
500MG 341 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Semaxanib
  • Note
    Research use only, not for human use.
  • Brief Description
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
  • Description
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SU5416
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2/Flk1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    194413-58-6
  • Formula Weight
    238.28
  • Molecular Formula
    C15H14N2O
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 2 mg/mL (8.39 mM); DMSO: 22 mg/mL (92.32 mM)
  • SMILES
    CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fong TA, et al. Y Res, 1999, 59(1), 99-106.
molnova catalog
related products
  • Sparteine sulfate

    Sparteine sulfate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.

  • Icrucumab

    Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.

  • (Z)-FeCP-oxindole

    (Z)-FeCP-oxindole is a selective inhibitor of VEGFR2 with an IC50 of 200 nM for humans and demonstrates anticancer activity.